

ANTIGENICS INC /DE/

Form 8-K

February 19, 2009

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

February 19, 2009

Date of Report (Date of earliest event reported)

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

(State or other jurisdiction  
of incorporation)

**000-29089**

(Commission  
File Number)

**06-1562417**

(IRS Employer  
Identification No.)

**3 Forbes Road**

**Lexington, MA**

(Address of principal executive offices)

**02421**

(Zip  
Code)

**781-674-4400**

(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item** Results of Operations and Financial Condition  
**2.02**

On February 19, 2009, Antigenics Inc. announced its financial results for the fourth quarter and year ended December 31, 2008. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item** Financial Statements and Exhibits  
**9.01**

(d)  
Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated February 19, 2009

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: February 19, 2009    By: /s/ Shalini Sharp

Shalini Sharp  
Chief Financial Officer

---

EXHIBIT INDEX

Exhibit No.   Description of Exhibit

99.1            Press Release dated February 19, 2009